In Re Diet Drugs (Phentermine/Fenfluramine/Dexfenluramine) Products Liability Litigation

573 F. App'x 186
CourtCourt of Appeals for the Third Circuit
DecidedJuly 15, 2014
Docket13-2340, 13-2341, 13-2584
StatusUnpublished

This text of 573 F. App'x 186 (In Re Diet Drugs (Phentermine/Fenfluramine/Dexfenluramine) Products Liability Litigation) is published on Counsel Stack Legal Research, covering Court of Appeals for the Third Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In Re Diet Drugs (Phentermine/Fenfluramine/Dexfenluramine) Products Liability Litigation, 573 F. App'x 186 (3d Cir. 2014).

Opinion

OPINION OF THE COURT

FISHER, Circuit Judge.

Jeanette Pearson (“Pearson”), Christeen Rightnar (“Rightnar”), and Janice Phillips (“Phillips”) (collectively, “Appellants”) appeal an Order 1 of the United States District Court for the Eastern District of Pennsylvania denying their recovery under the terms of the Diet Drug Nationwide Class Action Settlement Agreement (the “Settlement Agreement”). We will affirm.

I.

We write principally for the parties, who are familiar with the factual context and legal history of this case. Therefore, we will set forth only those facts necessary to our analysis.

This case is part of an ongoing multi-district litigation concerning a diet drug, called “Pondimin,” which was previously sold by Wyeth. 2 Pursuant to the Settlement Agreement, Wyeth was required to contribute funds for the payment of claims brought by individuals negatively affected by their diet drugs. The AHP Settlement Trust (the “Trust”) was responsible for administering and reviewing a claimant’s submissions to determine eligibility for benefits under the Settlement Agreement.

In order to qualify for compensation under the Settlement Agreement, a claimant must submit a completed Green Form to the Trust, which requires: (1) information from the claimant’s representative; (2) information regarding the claimant’s medical condition, to be completed by the claimant’s attesting physician; and (3) information from the claimant’s attorney where applicable. Appellants, who were each prescribed the diet drug and ingested it over the course of several months, individually sought compensation benefits under the Settlement Agreement.

In their Green Form submissions, Appellants’ physicians confirmed that each Appellant underwent an echocardiogram. Pearson’s physician noted that her echo-cardiogram showed moderate mitral regurgitation and an abnormal left a trial dimension. Both Rightnar’s and Phillips’s physicians noted that their echocardio-grams demonstrated moderate mitral regurgitation and an ejection fraction of 50-60%.

The Trust referred Pearson’s Green Form submission to its auditing cardiologist, who concluded that there was no reasonable medical basis for her attesting physician’s conclusions. Pearson sent additional information (i.e., affidavits from two other cardiologists) in hopes of a different response, but she received the same response. The auditing cardiologist who reviewed Rightnar’s Green Form submission at first concluded that her attesting physician’s conclusions had a reasonable medical basis. However, her claim fell into a category that required re-auditing 3 *188 of claims and was later denied due to lack of a reasonable medical basis for her attesting physician’s notations. Rightnar’s attempts to submit additional affidavits from three other cardiologists likewise failed. Phillips’ auditing cardiologist also concluded that there was no reasonable medical basis for her attesting physician’s conclusions regarding her ejection fraction, but he did find a reasonable medical basis for his answer of moderate mitral regurgitation. Her claim was denied based upon the auditing cardiologist’s finding regarding her ejection fraction and her additional attempts to submit affidavits were rejected.

Following their respective denials, Appellants filed notices of dispute regarding the Trust’s audit determinations. The Trust then applied for an Order from the District Court requiring Appellants to Show Cause as to why their claims should be eligible under the Settlement Agreement. The District Court issued that Order and referred each claim to the Special Master for further proceedings.

The Special Master assigned a Technical Advisor 4 to review all documents submitted by the Trust and the claimants and to prepare a report for the District Court. In those reports, the Technical Advisor concluded that there was no reasonable medical basis for Pearson’s attesting physician’s representation that she had moderate mitral regurgitation, and that there was no reasonable medical basis for both Rightnar’s and Phillips’ attesting physicians’ representations that they had a reduced ejection fraction.

After reviewing the entire Show Cause record for each Appellant, which included the Technical Advisor’s reports, the District Court issued detailed Memorandum Opinions concluding that Appellants failed to meet their burden of proving that there was a reasonable medical basis for their attesting physicians’ findings. Three separate Orders were then entered affirming the Trust’s denials of their claims for benefits under the Settlement Agreement.

These appeals followed.

II.

The District Court had jurisdiction over all terms of the Settlement Agreement under 28 U.S.C. §§ 1332 and 1407. We exercise jurisdiction over a final order of the District Court under 28 U.S.C. § 1291.

“We review a [djistrict [cjourt’s exercise of its equitable authority to administer and implement a class action settlement for abuse of discretion.” In re Diet Drugs, 543 F.3d 179, 184 n. 10 (3d Cir.2008) (citing In re Cendant Corp. Prides Litig., 233 F.3d 188, 192 (3d Cir.2000)). “[Tjo find an abuse of discretion [a] [djistrict [cjourt’s decision must rest on ‘a clearly erroneous finding of fact, an errant conclusion of law or an improper application of law to fact.’ ” Id. (quoting In re Nutraquest, Inc., 434 F.3d 639, 645 (3d Cir.2006)).

III.

Appellants set forth two arguments on appeal: (1) that the District Court abused its discretion in concluding that there was no reasonable medical basis for their attesting physicians’ Green Form findings; and (2) that the District Court abused its discretion by allowing the Technical Advis- *189 or to submit new evidence and resolve a disputed issue of fact. We disagree with both of these contentions.

1.

“Once the Trust denies a claim and the claim advances to a show cause proceeding, the claimant has the burden of proving there was a reasonable medical basis for the attesting physician’s representations.” Id. at 189; see also App. at A1785. The District Court in the instant proceedings both acknowledged and applied this standard in each of its Orders.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Cite This Page — Counsel Stack

Bluebook (online)
573 F. App'x 186, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-diet-drugs-phenterminefenfluraminedexfenluramine-products-ca3-2014.